Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-43.68
Price to sales ratio
0.69

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3073
EOLS
Evolus, Inc. - Common Stock
6.12 USD+1.16%-2.39%-11.05%-4.08%403.03 M USD
3102
CGC
Canopy Growth Corporation - Common Shares
0.93 USD-3.12%+3.33%-7.00%-40.76%392.60 M USD
3188
AKBA
Akebia Therapeutics, Inc. - Common Stock
1.32 USD+0.76%+4.76%+5.60%+11.86%354.10 M USD
3331
ORGO
Organogenesis Holdings Inc. - Class A
2.37 USD+1.28%-6.69%0.00%-44.76%304.96 M USD

Frequently asked questions about Emergent BioSolutions Inc. Common Stock

What is the Emergent BioSolutions Inc. Common Stock stock price today?

The current price of Emergent BioSolutions Inc. Common Stock (EBS) is 7.57. Over the past 24 hours, the stock has changed by +2.16%. Follow the EBS chart for real-time price dynamics.

What is the stock ticker of Emergent BioSolutions Inc. Common Stock?

Emergent BioSolutions Inc. Common Stock trades under the ticker EBS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Emergent BioSolutions Inc. Common Stock stock going up?

EBS has changed by +4.27% over the last week, -8.80% over the last month, and -29.38% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Emergent BioSolutions Inc. Common Stock?

Emergent BioSolutions Inc. Common Stock currently has a market capitalization of 390.58 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Emergent BioSolutions Inc. Common Stock earnings last quarter?

Last quarter, Emergent BioSolutions Inc. Common Stock reported earnings of 0.13 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Emergent BioSolutions Inc. Common Stock revenue for the last quarter?

Emergent BioSolutions Inc. Common Stock reported quarterly revenue of 156.1 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Emergent BioSolutions Inc. Common Stock net income for the last quarter?

Emergent BioSolutions Inc. Common Stock reported net income of 6.8 M for the last quarter. The previous quarter showed -54.6 M, which means net income changed by +112.45%.

How many employees does Emergent BioSolutions Inc. Common Stock have?

As of the latest available data, Emergent BioSolutions Inc. Common Stock has 900 employees. Workforce size can provide additional context about the company's scale and operations.

What is Emergent BioSolutions Inc. Common Stock EBITDA?

Emergent BioSolutions Inc. Common Stock EBITDA is -85.4 M, and its EBITDA margin is -54.71%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Emergent BioSolutions Inc. Common Stock stock?

You can buy Emergent BioSolutions Inc. Common Stock (EBS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Emergent BioSolutions Inc. Common Stock stock?

Investing in Emergent BioSolutions Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the EBS chart and related analysis on metatrader.com as part of your research.

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

News